Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (54) clinical trials

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

PRIMARY OBJECTIVES: I. To determine the safety of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1 therapy (MEDI4736 [durvalumab]) is safe in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin. (Lead-in) II. To test the hypothesis that concurrent RT and anti-PD-L1 therapy improves progression ...

Phase

IRX-2 Regimen and Durvalumab for Incurable H&N Squamous Cell Carcinoma

Study Population: Patients with histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of oral cavity, oropharynx, paranasal sinuses, hypopharynx, or larynx that is not amenable to local therapy with curative intent. Squamous cell carcinoma of unknown primary in cervical lymph node can be included only if p16 status ...

Phase

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy

PRIMARY OBJECTIVE: To estimate the overall response rate (ORR) of patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) who receive the combination of pembrolizumab and cabozantinib. SECONDARY OBJECTIVES: To estimate the progression-free survival (PFS) of patients treated with the combination of pembrolizumab and cabozantinib. To ...

Phase

Sapanisertib Carboplatin and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of the combination of sapanisertib (TAK-228 [MLN0128]) plus paclitaxel, when given with carboplatin, and to determine the optimal dose triplet, or maximum tolerated dose (MTD), in patients with advanced cancers refractory to standard therapy. SECONDARY OBJECTIVES: I. To assess the clinical ...

Phase